Overview
AbolerIS Pharma develops potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset. The company is advancing a novel class of antibodies targeting CD45RC, with its lead program ABO21009 in Phase 1, designed to treat rheumatoid arthritis, inflammatory bowel disease, and organ transplantation rejection.
Key people
In the news
- We’re looking forward to Dutch Medicines Days 2026! AbolerIS Pharma Chief Medical Officer Ronald Van Brempt, MD, will present “Immune Tolerance, Restored – Towards a Cure for Autoimmune Diseases” during the From Mechanism to First-in-Human: Immunopharmacology Today session. 📍 Corpus Conference Center, Leiden 📅 October 7–8, 2026 #DutchMedicinesDays #Immunology #AutoimmuneDisease #Aboleris
- AbolerIS Pharma and its collaborators from the VIB Center for inflammation Research and Ghent University Hospital are participating in the 17th International Symposium on Sjögren’s Disease in Paris this week. The team will present a poster highlighting their scientific work on CD45RC expression in salivary glands and its correlation with lymphocytic infiltration in Sjögren’s disease. #Autoimmune #HealthcareInnovation #AbolerISPharma #InternationalSymposiumSjogrensDisease
- We’re proud to share that Carole Guillonneau has been invited to present the work of AbolerIS Pharma at the Sixth Newcastle Therapeutic Tolerance Workshop in Newcastle upon Tyne, UK. Carole Guillonneau, Ph.D., AbolerIS Founder & Head of Research, will present new data on “Targeting CD45RC for Tolerance”, exploring the therapeutic potential of CD45RC targeting to induce immune tolerance in transplantation and autoimmune diseases. The workshop brings together leading academic and industry experts developing next-generation
- We’re proud to share that Carole Guillonneau has been invited to present the work of AbolerIS Pharma at the Sixth Newcastle Therapeutic Tolerance Workshop in Newcastle upon Tyne, UK. Carole Guillonneau, Ph.D., AbolerIS Founder & Head of Research, will present new data on “Targeting CD45RC for Tolerance”, exploring the therapeutic potential of CD45RC targeting to induce immune tolerance in transplantation and autoimmune diseases. The workshop brings together leading academic and industry experts developing next-generation
Alumni 1 went on to found or lead
- PIgnacio AnegonCo-Founder and Senior Consultant of AbolerIS Pharma (http://aboleris-pharma.com/)→Vice-President FOCIS at Federation of Clinical Immunology Societies (FOCIS)
Something wrong or missing? Send an update. Fixed within 24 hours.